| Literature DB >> 34322977 |
Efsun Tanacan1, Ogulcan Ibis1, Gulhan Aksoy Sarac1, Mehmet Ali Can Emeksiz1, Didem Dincer1, Fatma Gulru Erdogan1.
Abstract
BACKGROUND: To evaluate the perspectives of dermatology specialists and residents on coronavirus disease 2019 (COVID-19) vaccines.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34322977 PMCID: PMC8420361 DOI: 10.1111/ijcp.14666
Source DB: PubMed Journal: Int J Clin Pract ISSN: 1368-5031 Impact factor: 3.149
Comparison of demographic features, clinical characteristics and working conditions between the groups
| Variables |
Group 1 (resident) (n = 138) |
Group 2 (specialist) (n = 159) |
|
|---|---|---|---|
| Age (years)(median, IQR) | 29 (3) | 37 (12) |
|
|
| |||
| Male | 71 (51.4%) | 35 (22.01%) |
|
| Female | 67 (48.5%) | 124 (77.9%) | |
|
| |||
| Single | 92 (66.6%) | 28 (17.6%) |
|
| Married | 46 (33.3%) | 131 (82.3%) | |
|
| |||
| <25 | 82 (59.4%) | 68 (42.7%) |
. |
| 25‐29.9 | 46 (33.3%) | 57 (35.8%) | |
| 30‐34.9 | 10 (7.2%) | 27 (16.9%) | |
| 35‐39.9 | 0 | 1 (0.6%) | |
| ≥40 | 0 | 6 (3.7%) | |
|
| |||
| <1 | 16 (11.6%) | 0 |
|
| 1‐5 | 86 (62.3%) | 8 (5%) | |
| 5‐10 | 36 (26%) | 53(33.3%) | |
| 10‐20 | 0 | 57 (35.8%) | |
| >20 | 0 | 41 (25.7%) | |
|
| |||
| Not working | 0 | 4 |
|
| State hospital | 53 (38.4%) | 67 (42.1%) | |
| University hospital |
85 (61.5%) | 40 (25.1%) | |
| Private hospital | 0 | 31 (19.4%) | |
| Private office | 0 | 17 (10.6%) | |
|
| |||
| <50 | 25 (18.1%) | 36 (22.6%) |
|
| 50‐100 | 13 (9.4%) | 49 (30.8%) | |
| 100‐200 | 46 (33.3%) | 33 (20.8%) | |
| >200 | 54 (39.1%) | 41 (25.8%) | |
|
| |||
| <10 | 48 (34.8%) | 65 (40.9%) |
. |
| 10‐50 | 70 (50.7%) | 83 (52.2%) | |
| 50‐100 | 12 (8.7%) | 9 (5.7%) | |
| >100 | 8 (5.8%) | 2 (1.3%) | |
|
| |||
| Yes | 24 (17.4%) | 24 (15.1%) |
. |
| No | 110 (79.7%) | 126 (79.2%) | |
| Exsmoking | 4 (2.9%) | 9 (5.7%) | |
|
| |||
| Never | 54 (39.1%) | 74 (46.5%) |
|
| 1‐3 times per months | 84 (60.9%) | 63 (39.6%) | |
| 1‐5 times per weeks | 0 | 20 (12.6%) | |
| Almost every day | 0 | 2 (1.3%) | |
|
| |||
| Yes | 15 (10.9%) | 56 (35.2%) |
|
| No | 123 (89.1%) | 103 (64.8%) | |
|
| |||
| Yes | 54 (39.1%) | 76 (47.8%) | . |
| No | 18 (13%) | 22 (13.8%) | |
| Partially | 66 (47.8%) | 61 (38.4%) | |
|
| |||
| Yes | 52 (37.7%) | 92 (57.9%) |
|
| No | 86 (62.3%) | 67 (42.1%) | |
|
| |||
| Not exercise regularly | 68 (49.3%) | 94 (59.1%) |
.001 |
| <1 hour/per week | 10 (7.2%) | 13 (8.2%) | |
| 1‐2 hour/per week | 16 (11.6%) | 24 (15.1%) | |
| 2‐4 hours/ per week | 36 (26.1%) | 13 (8.3%) | |
| >4 hours/per week | 8 (5.8%) | 15 (9.4%) | |
|
| |||
| 1 | 64 (46.4%) | 18 (11.3%) |
|
| 2 | 36 (26.1%) | 43 (27%) | |
| 3 | 34 (24.6%) | 43 (27%) | |
| 4 | 4 (2.9%) | 36 (22.6%) | |
| 5 | 0 (0%) | 12 (7.5%) | |
| ≥6 | 0 (0%) | 7 (2.4%) | |
|
| |||
| Yes | 4 (2.9%) | 23 (14.5%) |
|
| No | 134 (97.1) | 136 (85.5%) | |
|
| |||
| Dermatology clinics and polyclinics | 6(4.3%) | 74 (46.5%) |
|
| Covid‐19 clinic, polyclinic and emergency | 0 (0%) | 4 (2.5%) | |
| Dermatology clinics/ polyclinics and Covid‐19 clinic, polyclinic and emergency | 132 (95.7%) | 66 (41.5%) | |
| Other | 0 (0%) | 15 (9.4%) | |
Statistical analysis was performed by Mann–Whitney U test.
Statistical analysis was performed by Chi‐square test.
P values < 0.05 were highlighted in bold.
Comparison of questionnary answers between the groups
| Variables |
Group 1(resident) (n = 138) |
Group 2 (specialist) (n = 159) |
|
|---|---|---|---|
|
| |||
| Sufficient | 14 (10.1%) | 43 (27%) |
. |
| Intermediate | 92 (66.7%) | 84 (52.8%) | |
| Unsufficient | 32 (23.2%) | 32 (20.1%) | |
|
| |||
| Online education − webinar | 30 (21.7%) | 26 (16.4%) |
. |
| Reading literature | 32 (23.2%) | 36 (22.6%) | |
| Social Media | 48 (34.8%) | 58 (36.5%) | |
| Corporate trainings | 0 | 3 (1.9%) | |
| Literature + social media | 8 (5.8%) | 7 (4.4%) | |
| Online education − webinar + Corporate trainings | 0 | 1 (0.6%) | |
| Online education − webinar +literature | 4 (2.9%) | 4 (2.5%) | |
| Literature + Corporate trainings | 4 (2.9%) | 0 | |
| Online education − webinar +literature+ Corporate trainings | 0 | 4 (2.5%) | |
| Online education − webinar +literature+social media | 4 (2.9%) | 7 (4.4%) | |
| Online education − webinar +literature+social media + Corporate trainings | 8 (5.8%) | 3 (1.9%) | |
| Other | 0 | 3 (1.9%) | |
|
| |||
| Yes | 46 (33.3%) | 34 (21.4%) |
.003 |
| No | 88 (63.8%) | 107 (67.3%) | |
| I am thinking of having it done | 4 (2.9%) | 18 (11.3%) | |
|
| |||
| Yes | 16 (11.6%) | 19 (11.9%) |
.086 |
| No | 118 (85.5%) | 126(79.2%) | |
| I am thinking of having it done | 4 (2.9%) | 14 (8.8%) | |
|
| |||
| Yes | 90 (65.2%) | 61 (38.4%) |
<.001 |
| No | 48 (34.8%) | 98 (61.6%) | |
|
| |||
| Yes | 26 (18.8%) | 18 (11.3%) |
.069 |
| No | 112 (81.2%) | 141 (88.7%) | |
|
| |||
| I think if most of my colleagues get it done | 26 (18.8%) | 35 (22%) |
0.012 |
| I think according to the results on a sufficient number of patients | 52 (32.7%) | 75 (47.2%) | |
| I am thinking of getting the Covid‐19 vaccinec | 40 (29 %) | 19 (11.9%) | |
| Under no circumstancesd | 4 (2.9%) | 3 (1.9%) | |
| I have not decided yete | 12 (8.7%) | 20 (12.6%) | |
| a+b | 4 (2.9%) | 7 (4.4%) | |
| a+e | 0 (0%) | 1 (0.06%) | |
| b+c | 0 (0%) | 3 (1.9%) | |
|
| |||
| No | 24 (17.4%) | 11 (6.9%) |
.035 |
| I would only want under 18s to be vaccinated | 0 (0%) | 0 (0%) | |
| I would like those aged 65 and over and those with chronic diseases to be vaccinated | 30 (21.7%) | 41 (25.8%) | |
| I would like all family members to be vaccinated | 84 (60.9%) | 107 (67.2%) | |
|
| |||
| The vaccine itself could cause illness | 0 | 3 (1.9%) |
.011 |
| Vaccine‐related side effects | 24(17.4%) | 23 (14.5%) | |
| It has not been applied to a sufficient number of individuals beforec | 38 (27.5%) | 47 (29.6%) | |
| Concern that the vaccine may have harmful effects in the long termd | 14 (10.1%) | 21 (13.2%) | |
| The vaccine is ineffectivee | 36 (26.1%) | 20 (12.6%) | |
| b+c+e | 26 (18.8%) | 45 (28.3%) | |
|
| |||
| 0‐3 | 28 (20.3%) | 16 (10.1%) |
<.001 |
| 4‐6 | 54 (39.1%) | 40 (25.2%) | |
| 7‐10 | 56 (40.6%) | 103 (64.8%) | |
| If you think the vaccine will be beneficial, what factor would you give as the most apparent reason for this? | |||
| I think it will end the pandemic | 22 (15.9%) | 40 (25.2%) |
.065 |
| I believe it will effectively protect my loved ones and me against illness | 24 (17.4%) | 17 (10.7%) | |
| I think the vaccine will reduce the severity and complications of the disease | 64 (46.4%) | 76 (47.8%) | |
| I don't think the vaccine will be helpful | 16 (11.6%) | 9 (5.7%) | |
| a+b | 12 (8.7%) | 17 (10.7%) | |
|
| |||
| Inactive vaccines (dead‐virus vaccine) | 96 (69.6%) | 67 (42.1%) |
<.001 |
| mRNA vaccines | 4 (2.9%) | 29 (18.2%) | |
| Viral vector (adenovirus vaccines)c | 0 (0%) | 1 (0.6%) | |
| I wouldn't prefer any of them | 16 (11.6%) | 7 (4.4%) | |
| It does not matter | 10 (7.2%) | 37 (23.3%) | |
| a+b | 8 (5.8%) | 18 (11.3%) | |
| a+c | 4 (2.9%) | 0 (0%) | |
Statistical analysis was performed by Mann–Whitney U test.
Statistical analysis was performed by Chi‐square test.
P values < 0.05 were highlighted in bold.
Correlations analyses between acceptance of vaccination and various study parameters
| Parameters |
|
|
|---|---|---|
| Age | −.127 | .028 |
| Chronic diseases and medication | .133 | .021 |
| Duration of medical practice | −.132 | .041 |
| Level of knowledge about COVID‐19 vaccines | .207 | <.001 |
| Number of information sources about COVID‐19 | .335 | <.001 |
| Previous COVID‐19 infection | .176 | .002 |